Chimeric antigen receptor-modified T cells targeting BAFF-R / CD19 and uses thereof

Dual-targeting CAR-T cells addressing CD19 and BAFF-R antigens provide a solution to relapse issues in CD19-targeted therapies by enhancing tumor recognition and cytotoxicity, improving treatment outcomes in B-ALL and lymphoma.

JP7593646B2Active Publication Date: 2024-12-03CITY OF HOPE
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021548701
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-20
Filing Date
2020-02-20
Publication Date
2024-12-03
Estimated Expiration
2040-02-20

AI Technical Summary

Technical Problem

CD19-targeted CAR-T cell therapy for B-ALL and lymphoma is effective but faces relapse due to antigen-defective mutants, and CD22 CAR-T therapy is limited by variable expression density, especially in mixed leukemia (MLL), with expression decreasing post-therapy.

Method used

Development of T cells expressing chimeric antigen receptors (CARs) targeting both BAFF-R and CD19, utilizing tandem or loop formats with specific scFvs and domains for enhanced targeting, including a spacer sequence and costimulatory and signaling domains.

Benefits of technology

The dual-targeting CARs demonstrate improved efficacy against B-cell malignancies by effectively targeting both BAFF-R and CD19, showing enhanced cytotoxicity and survival benefits in preclinical models, particularly in mixed B-ALL tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593646000030
    Figure 0007593646000030
  • Figure 0007593646000031
    Figure 0007593646000031
  • Figure 0007593646000032
    Figure 0007593646000032
Patent Text Reader

Abstract

A chimeric antigen receptor that targets both BAFF-R and CD19 and methods of using the same are described.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Immunotherapy using tumor-specific T cells, including therapy using genetically engineered T cells, is being investigated for antitumor treatment. [Background technology]

[0002] CD19 CAR-T cell therapy is effective in many B-ALL and lymphoma patients. However, relapse due to antigen-deficient variants that escape CD19-targeted CAR-T therapy can occur in up to 20-30% of patients. CD22 CAR-T cell therapy has been proposed as one of the alternative strategies to overcome relapse from CD19 antigen loss, as evidenced by the clinical response achieved in CD19-negative B-ALL patients. However, it has been reported that the expression density of CD22 is altered, especially in mixed lineage leukemia (MLL), and its expression is decreased after CD22-targeted therapy. Summary of the Invention

[0003] Described herein are methods of treating B-cell malignancies, including B-ALL and lymphoma, using T cells expressing chimeric antigen receptors (CARs) that target B-cell activating factor receptor (BAFF-R) and CD19. In some cases, a single CAR targets both BAFF-R and CD19. In the case of a single CAR that targets both BAFF-R and CD19, the extracellular targeting moiety can be in a tandem format, where an scFv against one target precedes the other scFv, or in a loop format, where an scFv against one of the two targets is placed between the VL and VH domains of the scFv against the other target. In any of these formats, the CAR includes a transmembrane domain (e.g., a CD8 transmembrane domain), a costimulatory domain (e.g., a 4-1BB costimulatory domain), and a CD3 zeta signaling domain. The CAR may also comprise spacer sequences, for example, between the scFv domain and the transmembrane domain, between the transmembrane domain and the costimulatory domain, and / or between the costimulatory domain and the CD3 zeta signaling domain.

[0004] Described herein is a nucleic acid molecule comprising a nucleotide sequence encoding a chimeric antigen receptor that is targeted to both BAFF-R and CD19, the chimeric antigen receptor comprising, from amino terminus to carboxy terminus, a targeting domain that targets BAFF-R and CD19; a spacer domain; a transmembrane domain; a costimulatory domain; and a CD3ζ signaling domain.

[0005] In various embodiments, (1) the targeting domain comprises, from the amino terminus to the carboxy terminus: a) an scFv targeted to BAFF-R and an scFv targeted to CD19; or b) an scFv targeted to CD19 and an scFv targeted to BAFF-R; (2) the targeting domain comprises, from the amino terminus to the carboxy terminus: a) the VL domain of CD19 scFv; an scFv targeted to BAFF-R; and the VH of CD19 scFv; or (b) the VH domain of CD19 scFv; an scFv targeted to BAFF-R; and the VL of CD19 scFv; and (3) the targeting domain comprises, from the amino terminus to the carboxy terminus: a) the VL domain of BAFF-R scFv; an scFv targeted to CD19; and the VH of BAFFF; or (b) the VH domain of BAFF. -R scFv; an scFv targeting CD19; and the VL of BAFF-R scFv.

[0006] Also described herein are nucleic acid molecules comprising nucleotide sequences encoding both a chimeric antigen receptor that targets BAFF-R and a chimeric antigen receptor that targets CD19, where the chimeric antigen receptor that targets BAFF-R comprises, from amino to carboxy terminus: a BAFF-R scFv; a spacer domain; a transmembrane domain; a costimulatory domain; and a CD3 zeta signaling domain, and the chimeric antigen receptor that targets CD19 comprises, from amino to carboxy terminus: a CD19 scFv; a spacer domain; a transmembrane domain; a costimulatory domain; and a CD3 zeta signaling domain.

[0007] In various embodiments, the costimulatory domain is selected from the group consisting of a CD28 costimulatory domain or variant thereof with one to five amino acid modifications, a 4-1BB costimulatory domain or variant thereof with one to five amino acid modifications, and an OX40 costimulatory domain or variant thereof with one to five amino acid modifications; the transmembrane domain is selected from a CD4 transmembrane domain or variant thereof with one to five amino acid modifications, a CD8 transmembrane domain or variant thereof with one to five amino acid modifications, a CD28 transmembrane domain or variant thereof with one to five amino acid modifications, and a CD3 ζ transmembrane domain or variant thereof with one to five amino acid modifications; and the spacer domain is selected from an IgG4 The IgG4 hinge is selected from the group consisting of: hinge (S→P), IgG4 hinge, IgG4(S228P)+linker, CD28 hinge, CD8 hinge-48aa, CD8 hinge-45aa, IgG4(HL-CH3), IgG4(L235E, N297Q), IgG4(S228P, L235E, N297Q), IgG4(CH3), and each mutant of IgG4 hinge (S→P), IgG4 hinge, IgG4 hinge (S228P)+linker, CD28 hinge, CD8 hinge-48aa, CD8 hinge-45aa, IgG4(HL-CH3), IgG4(L235E, N297Q), IgG4(S228P, L235E, N297Q), and IgG4(CH3) in which 1 to 5 amino acids have been modified.

[0008] In various embodiments, (1) the BAFF-R scFv comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises CDR L1 (SEQ ID NO:1), CDR L2 (SEQ ID NO:2) and CDR L3 (SEQ ID NO:3), and the heavy chain variable region comprises CDR H1 (SEQ ID NO:4), CDR H2 (SEQ ID NO:5) and CDR H3 (SEQ ID NO:6); (2) the BAFF-R scFv comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises CDR L1 (SEQ ID NO:7), CDR L2 (SEQ ID NO:8) and CDR L3 (SEQ ID NO:9), and the heavy chain variable region comprises CDR H1 (SEQ ID NO:10), CDR H2 (SEQ ID NO:11) and CDR H3 (SEQ ID NO:11). (3) BAFF-R scFv comprises a heavy chain variable domain selected from Chi90 HC, Hu90 HC-1, Hu90 HC-2, Hu90 HC-3, Chi55 HC, Hu55 HC-1, Hu55 HC-2, and Hu55 HC-3, and a light chain variable domain selected from Chi90 LC, Hu90 LC-1, Hu90 LC-2, Hu90 LC-3, Chi55 LC, Hu55 LC-1, Hu55 LC-2, and Hu55 LC-3; (4) BAFF-R scFv comprises a light chain variable domain having an amino acid sequence selected from SEQ ID NOs: 17 to 20 and 25 to 28; (5) BAFF-R scFv comprises a heavy chain variable domain having an amino acid sequence selected from SEQ ID NOs: 13-16 and 21-24; (6) CD19 The scFv comprises a VL comprising the following amino acid sequence: DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDQTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFC QQGNTLPYTFGGGTKLEIT (SEQ ID NO: 30) and a VH comprising EVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGG SYAMDYWGQQTSVTVSS (SEQ ID NO: 31).

[0009] Also described herein are vectors comprising one or more of the above nucleic acid molecules. In various embodiments, the vector is a lentiviral vector. Also described herein are populations of human T cells transduced by the vectors described.

[0010] Also described herein is a method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising a population of human T cells. In various embodiments of the method, the cancer is lymphoma, leukemia, or myeloma; the lymphoma is mantle cell lymphoma, follicular large B-cell lymphoma, marginal zone lymphoma, or Burkitt's lymphoma; the leukemia is acute lymphoblastic leukemia, chronic lymphocytic leukemia, or hairy cell leukemia; the myeloma is multiple myeloma; the population of T cells is autologous or allogeneic to the patient; and the population of human T cells comprises CD4+ cells and CD8+ cells.

[0011] In one embodiment, the BAFF-R scFv includes a light chain variable region and a heavy chain variable region, the light chain variable region includes CDR L1 shown in SEQ ID NO: 7, CDR L2 shown in SEQ ID NO: 8, and CDR L3 shown in SEQ ID NO: 9, and the heavy chain variable region includes CDR H1 shown in SEQ ID NO: 10, CDR H2 shown in SEQ ID NO: 11, and CDR H3 shown in SEQ ID NO: 12. In an embodiment, the antibody is a humanized antibody.

[0012] In one embodiment, the BAFF-R scFv includes CDR L1 of SEQ ID NO: 1 or 7, CDR L2 of SEQ ID NO: 2 or 8, CDR L3 of SEQ ID NO: 3 or 9, CDR H1 of SEQ ID NO: 4 or 10, CDR H2 of SEQ ID NO: 5 or 11, and CDR H3 of SEQ ID NO: 7 or 13.

[0013] In certain embodiments, portions of the BAFF-R scFv include the following: the light chain variable domain of monoclonal antibody H90, the heavy chain variable domain of monoclonal antibody H90, or the light chain variable domain of monoclonal antibody H55, and the heavy chain variable domain of monoclonal antibody H55. The heavy chain variable domain and the light chain variable domain can be linked by a linker of 5 to 100, 10 to 50, or 10 to 20 amino acids (e.g., GGGSGGGGSGGGGS).

[0014] In some embodiments, the BAFF-R scFv comprises: a) a humanized variant of the light chain variable domain of monoclonal antibody H90, and a humanized variant of the heavy chain variable domain of monoclonal antibody H90; or b) a humanized variant of the light chain variable domain of monoclonal antibody H55, and a humanized variant of the heavy chain variable domain of monoclonal antibody H55. The heavy chain variable domain and the light chain variable domain can be linked by a linker of 10 to 20 amino acids (e.g., GGGSGGGGSGGGGS). In some cases, the humanized variant of the H90 light chain variable domain is selected from Hu90 LC-1, Hu90 LC-2, and Hu90 LC-3, and the humanized variant of the H90 heavy chain variable domain is selected from Hu90 HC-1, Hu90 HC-2, and Hu90 HC-3. In some cases, the humanized variant of the H55 light chain variable domain is selected from Hu55 LC-1, Hu55 LC-2, and Hu55 LC-3, and the humanized variant of the H55 heavy chain variable domain is selected from Hu55 HC-1, Hu55 HC-2, and Hu90 HC-3.

[0015] In embodiments, the BAFF-R scFv light chain variable region comprises a serine at a position corresponding to Kabat position 7. In embodiments, the light chain variable region comprises a proline at a position corresponding to Kabat position 8. In embodiments, the light chain variable region comprises a valine at a position corresponding to Kabat position 15. In embodiments, the light chain variable region comprises a threonine at a position corresponding to Kabat position 22. In embodiments, the light chain variable region comprises a glutamine at a position corresponding to Kabat position 24. In embodiments, the light chain variable region comprises a glycine at a position corresponding to Kabat position 41. In embodiments, the light chain variable region comprises a lysine at a position corresponding to Kabat position 42. In embodiments, the light chain variable region comprises an alanine at a position corresponding to Kabat position 43. In embodiments, the light chain variable region comprises a proline at a position corresponding to Kabat position 44. In embodiments, the light chain variable region comprises a threonine at a position corresponding to Kabat position 56. In embodiments, the light chain variable region comprises a threonine at a position corresponding to Kabat position 72. In embodiments, the light chain variable region comprises a phenylalanine at a position corresponding to Kabat position 73. In embodiments, the light chain variable region comprises a glutamine at a position corresponding to Kabat position 79. In embodiments, the light chain variable region comprises a valine at a position corresponding to Kabat position 104.

[0016] In embodiments, the BAFF-R scFv light chain variable region comprises a serine at a position corresponding to Kabat position 7, a proline at a position corresponding to Kabat position 8, a valine at a position corresponding to Kabat position 15, a threonine at a position corresponding to Kabat position 22, a glutamine or serine at a position corresponding to Kabat position 24, a glycine at a position corresponding to Kabat position 41, a lysine at a position corresponding to Kabat position 42, an alanine or threonine at a position corresponding to Kabat position 43, a proline at a position corresponding to Kabat position 44, a threonine at a position corresponding to Kabat position 56, a threonine, phenylalanine or lysine at a position corresponding to Kabat position 72, a glutamine at a position corresponding to Kabat position 73, a glutamine at a position corresponding to Kabat position 79, or a valine at a position corresponding to Kabat position 104.

[0017] In embodiments, the BAFF-R scFv light chain variable region comprises binding framework region residues that include a serine at a position corresponding to Kabat position 7, a proline at a position corresponding to Kabat position 8, a valine at a position corresponding to Kabat position 15, a threonine at a position corresponding to Kabat position 22, a glutamine or serine at a position corresponding to Kabat position 24, a glycine at a position corresponding to Kabat position 41, a lysine at a position corresponding to Kabat position 42, an alanine or threonine at a position corresponding to Kabat position 43, a proline at a position corresponding to Kabat position 44, a threonine at a position corresponding to Kabat position 56, a threonine, phenylalanine or lysine at a position corresponding to Kabat position 72, a glutamine at a position corresponding to Kabat position 73, a glutamine at a position corresponding to Kabat position 79, or a valine at a position corresponding to Kabat position 104.

[0018] In embodiments, the BAFF-R scFv heavy chain variable region comprises a threonine or an alanine at a position corresponding to Kabat position 10. In embodiments, the heavy chain variable region comprises a lysine at a position corresponding to Kabat position 11. In embodiments, the heavy chain variable region comprises a valine at a position corresponding to Kabat position 12. In embodiments, the heavy chain variable region comprises a threonine at a position corresponding to Kabat position 15. In embodiments, the heavy chain variable region comprises a threonine at a position corresponding to Kabat position 19. In embodiments, the heavy chain variable region comprises a threonine at a position corresponding to Kabat position 23. In embodiments, the heavy chain variable region comprises a proline at a position corresponding to Kabat position 41. In embodiments, the heavy chain variable region comprises an alanine at a position corresponding to Kabat position 44. In embodiments, the heavy chain variable region comprises a proline or threonine at a position corresponding to Kabat position 61. In embodiments, the heavy chain variable region comprises an arginine at a position corresponding to Kabat position 66. In embodiments, the heavy chain variable region comprises a threonine at a position corresponding to Kabat position 70. In embodiments, the heavy chain variable region comprises a lysine at a position corresponding to Kabat position 75. In embodiments, the heavy chain variable region comprises a valine at a position corresponding to Kabat position 79. In embodiments, the heavy chain variable region comprises a threonine at a position corresponding to Kabat position 81. In embodiments, the heavy chain variable region comprises a methionine at a position corresponding to Kabat position 82. In embodiments, the heavy chain variable region comprises an asparagine at a position corresponding to Kabat position 82B. In embodiments, the heavy chain variable region comprises a methionine at a position corresponding to Kabat position 82C. In embodiments, the heavy chain variable region comprises a proline at a position corresponding to Kabat position 84. In embodiments, the heavy chain variable region comprises a valine at a position corresponding to Kabat position 85. In embodiments, the heavy chain variable region comprises a lysine at a position corresponding to Kabat position 108. In embodiments, the heavy chain variable region comprises a valine at a position corresponding to Kabat position 109.

[0019] In an embodiment, BAFF-R The scFv heavy chain variable region comprises a threonine or alanine at a position corresponding to Kabat position 10, a lysine at a position corresponding to Kabat position 11, a valine at a position corresponding to Kabat position 12, a threonine at a position corresponding to Kabat position 15, a threonine at a position corresponding to Kabat position 19, a threonine at a position corresponding to Kabat position 23, a proline at a position corresponding to Kabat position 41, an alanine at a position corresponding to Kabat position 44, a proline, serine or threonine at a position corresponding to Kabat position 61, an arginine at a position corresponding to Kabat position 66, a threonine at a position corresponding to Kabat position 70, a lysine at a position corresponding to Kabat position 75, a valine at a position corresponding to Kabat position 79, a threonine or lysine at a position corresponding to position 81, a methionine at a position corresponding to Kabat position 82, an asparagine at a position corresponding to Kabat position 82B, a methionine at a position corresponding to Kabat position 82C, a proline at a position corresponding to Kabat position 84, a valine at a position corresponding to Kabat position 85, a lysine at a position corresponding to Kabat position 108, or a valine at a position corresponding to Kabat position 109.

[0020] In embodiments, the BAFF-R scFv heavy chain variable region contains a threonine or alanine at the position corresponding to Kabat position 10, a lysine at the position corresponding to Kabat position 11, a valine at the position corresponding to Kabat position 12, a threonine at the position corresponding to Kabat position 15, a threonine at the position corresponding to Kabat position 19, a threonine at the position corresponding to Kabat position 23, a proline at the position corresponding to Kabat position 41, an alanine at the position corresponding to Kabat position 44, a proline, serine or threonine at the position corresponding to Kabat position 61, an arginine at the position corresponding to Kabat position 66, an arginine at the position corresponding to Kabat position 70, an arginine at the position corresponding to Kabat position 72, an arginine at the position corresponding to Kabat position 74, an arginine at the position corresponding to Kabat position 76, an arginine at the position corresponding to Kabat position 78, an arginine at the position corresponding to Kabat position 79, an arginine at the position corresponding to Kabat position 80, an arginine at the position corresponding to Kabat position 81, an arginine at the position corresponding to Kabat position 82, an arginine at the position corresponding to Kabat position 83, an arginine at the position corresponding to Kabat position 84, an arginine at the position corresponding to Kabat position 85, an arginine at the position corresponding to Kabat position 86, an arginine at the position corresponding to Kabat position 87, an arginine at the position corresponding to Kabat position 89, an arginine at the position corresponding to Kabat position 90, an arginine at the position corresponding to Kabat position 91, an arginine at the position corresponding to Kabat position 92, an arginine at the a threonine at a position corresponding to Kabat position 75, a lysine at a position corresponding to Kabat position 75, a valine at a position corresponding to Kabat position 79, a threonine or lysine at a position corresponding to Kabat position 81, a methionine at a position corresponding to Kabat position 82, an asparagine at a position corresponding to Kabat position 82B, a methionine at a position corresponding to Kabat position 82C, a proline at a position corresponding to Kabat position 84, a valine at a position corresponding to Kabat position 85, a lysine at a position corresponding to Kabat position 108, or a valine at a position corresponding to Kabat position 109. [Brief description of the drawings]

[0021] [Figure 1] Schematic diagram of two examples of tandem structures and one example of the loop structure of a BAFF-R / CD19 dual CAR. Also shown is an example of a bicistronic construct expressing two CARs, one targeting BAFF-R and the other targeting CD19.

[0022] [Diagram 2]5 shows the amino acid sequence of the immature 1250 dual CAR, including the signal sequence (SEQ ID NO: 58). The mature CAR (SEQ ID NO: 59) comprises, from amino to carboxy terminus, the following: BAFF-R scFv, linker, CD19 scFv (from FMC63), IgG4 (SmP / L235E,N297Q) spacer domain, CD4 transmembrane domain, 4-1BB cyto domain, GG linker, and CD3 signaling domain.

[0023] [Diagram 3] 6 shows the amino acid sequence of the immature 1296 dual CAR, including the signal sequence (SEQ ID NO: 60). The mature CAR (SEQ ID NO: 61) comprises, from amino to carboxy terminus, the following: CD19 scFv (from FMC63), linker, BAFF-R scFv, IgG4 (SmP / L235E,N297Q) spacer domain, CD4 transmembrane domain, 4-1BB cyto domain, GG linker, and CD3 signaling domain.

[0024] [Figure 4] 6 depicts the amino acid sequence of the immature 1316 dual CAR, including the signal sequence (SEQ ID NO: 62). The mature CAR (SEQ ID NO: 63) comprises, from amino to carboxy terminus, the following: CD19 VL (from FMC63), GGGS linker, BAFF-R scFv, CD19 VH (from FMC63), IgG4 (SmP / L235E,N297Q) spacer domain, CD4 transmembrane domain, 41BB cyto domain, GG linker, and CD3 signaling domain.

[0025] [Diagram 5](A) Amino acid sequences of immature CD19 CAR including signal sequence (SEQ ID NO:64) and immature BAFF-R CAR including signal sequence (SEQ ID NO:66). Mature CD19 CAR (SEQ ID NO:65) includes from amino to carboxy terminus: CD19 scFv (from FMC63), IgG4 (SmP / L235E,N297Q) spacer domain, CD28 transmembrane domain, CD28 (GG) cytoplasmic domain, GG linker, and CD3 signaling domain. Mature BAFF-R CAR (SEQ ID NO:67) includes from amino to carboxy terminus: BAFF-R scFv, IgG4 (SmP / L235E,N297Q) spacer domain, CD4 transmembrane domain, 4-1BB cytoplasmic domain, GGG linker, and CD3 signaling domain.

[0026] [Figure 6] Schematic diagram of an example vector expressing a BAFF-R / CD19 dual CAR. The BAFF-R and CD19 scFv elements can be altered to vary the sequence of the dual CAR. Truncated EGFR (EGFRt) is expressed as a selection marker.

[0027] [Figure 7] Figure 1 shows the results of a dual CAR expression study. T cells (Jurkat) were transduced with each CAR construct or an empty vector (mock). The cells were stained with protein L- or EGFR-APC binding antibodies. Protein L targets the variable light chain of the scFv and the truncated EGFR is co-expressed with the CAR vector. Constructs that can adequately express dual CARs were further explored. Dual CAR 1296 and dual CAR 1316 expressed the complete CAR and the EGFRt selection marker, whereas dual CAR 1250 did not express the complete CAR.

[0028] [Figure 8]Figure 1 shows the results of a FACS assay evaluating 1250 dual CAR T cell degranulation after incubation with target cells. Target cells were either BAFF-R single positive, CD19 single positive, or BAFF-R and CD19 double negative. Control BAFF-R single CAR and non-transduced T cells (non-CAR) were used as controls. 1250 dual CAR did not induce a response against BAFF-R positive L cells, suggesting that the BAFF-R targeting scFv was not properly expressed.

[0029] [Figure 9] Figure 1 shows the results of analyses related to the generation of cell lines used in the development of the BAFF-R / CD19 dual CAR research model. FACS histograms of the Nalm-6 knockout lines used in the dual CAR model development. The Nalm-6 B-ALL tumor line was CRISPR edited to knock out BAFF-R (left) or CD19 (right). Surface protein expression was confirmed by FACS staining with commercially available BAFF-R and CD19 antibodies. Nalm-6 wild type (WT) was used as a control.

[0030] [Figure 10]Figures 10A-10B show the results of an analysis of the CTL function of BAFF-R / CD19 dual CARs. The graph plots the specific lysis calculated from a cytotoxic T lymphocyte assay against the Nalm-6 ALL tumor line. The target cell line Nalm-6 (WT, CD19 knockout, or BAFF-R knockout mutant) was labeled with chromium-51 and incubated with effector CAR T cells. CARs included BAFF-R / CD19 dual target CARs: A. 1296 and 1250 or B. 1296 and 1316, and controls for both panels included single target CARs: BAFF-R CAR and CD19 CAR as well as non-transduced T cells (non-CAR, allogeneic control). All T cells were derived from a single healthy donor in each panel. Chromium released from target cells due to effector T cell function was measured in a gamma counter and calculated as a percentage of the maximum possible release. Experiments were performed in triplicate and analyzed by Student's t test, A. **P<0.001, and B. **P<0.001 c / w non-CAR control. 1250 CAR CTL dual data suggest possible BAFF-R targeting defect.

[0031] [Figure 11] 11A-11B show the activity of BAFF-R / CD19 dual CAR in BAFF-R plus CD19-deficient mixed B-ALL tumors. A) Bioluminescence images of NSG mice after IV tumor challenge on day 0 with a mixture of 1×105 RFP-negative, luciferase-expressing Nalm-6-CD19KO+2.5×105 RFP-positive, luciferase-expressing Nalm-6-BAFF-RKO tumor cells. Groups of 5 tumor mice were then randomized to treatment with either 2.5×106 CD4 TN CAR-T + 106 CD8 TN 1296 or 1316 dual CAR T cells / mouse IV on day 10, each as a single injection. Non-transduced CD4 / CD8 T cells from the same donor were used as allogeneic control (non-CAR). B) Kaplan-Meier plots of overall survival are shown. Log-rank test compares experimental groups as indicated. The survival benefit of 1316 treatment was significant compared with 1296 treatment.

[0032] [Figure 12] Figure 12: Activity of 1316 BAFF-R / CD19 dual CAR against knockout tumors. FACS plot of BAFF-R CAR T cell function measured by CD107a degranulation assay. CD4 or CD8 BAFF-R CAR T cells were co-incubated with either CD19BAFF-R+ Nalm-6 or CD19+ BAFF-RNalm-6 lines. Single target CD19 or BAFF-R CAR T cells were used as controls.

[0033] [Figure 13] Figures 13A-13B show the activity of TN / MEM 1316 BAFF-R / CD19 dual CAR in mixed B-ALL tumors. A) Bioluminescence images of NSG mice after IV tumor challenge on day 0 with a mixture of 1x105 RFP-negative, luciferase-expressing Nalm-6-CD19KO+1x105 RFP-positive, luciferase-expressing Nalm-6-BAFF-RKO tumor cells. Five tumor mice per group were then injected once with either low dose (2.8x106 TN / MEM), high dose (5.6x106 TN / MEM) to generate 1x106 and 2x106 BAFF-R CAR T cells, respectively, and randomized to 1316 dual CAR T cells / mouse intravenously on day 9. Or 5x106 non-transduced TN / MEM cells from the same donor were used as allogeneic control (non-CAR). B) Kaplan-Meier plots of overall survival. Log-rank tests compare experimental groups as indicated. No significant differences in survival were observed between the two doses. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0034] BAFF-R / CD19 dual CARs and BAFF-R / CD19 bicistronic CARs can use any of a variety of BAFF-R scFvs and CD19 scFvs, and in the case of BAFF-R / CD19 dual CARs where the first scFv is located between the variable domains of the second scFv, any of a variety of VL and VH can be used.

[0035] Figure 1 is a schematic diagram of two examples of tandem constructs in which the BAFF-R scFv is the amino terminus of the CD19 scFv and the CD19 scFv is the amino terminus of the BAFF-R scFv. Also shown is an example of a loop construct for a BAFF-R / CD29 dual CAR. In this example, the BAFF-R is located between the CD19 VL (amino terminus of the scFv) and the CD19 VH domain (carboxy terminus of the scFv). Also shown is an example of a bicistronic construct in which a cell expresses two CARs, one targeting BAFF-R and the other targeting CD19.

[0036] BAFF-R scFv sequence The BAFF-R scFv sequences used in the BAFF-R / CD19 dual CAR can be derived from two monoclonal antibodies, clone 90 and clone 55, which are described in detail in US PCT / US2017 / 036181. For example, the VL may comprise the C90 CDR sequence or the C55 CDR sequence described below.

[0037] C90 CDR L1: ESVDNYGISF (SEQ ID NO: 1)

[0038] C90 CDR L2: AAS (SEQ ID NO:2)

[0039] C90 CDR L3: QQSKEVPWT (SEQ ID NO:3)

[0040] C90 CDR H1: GDSITSGY (SEQ ID NO: 4)

[0041] C90 CDR H2: ISYSGST (SEQ ID NO:5)

[0042] C90 CDR H3: ASPNYPFYAMDY (SEQ ID NO:6)

[0043] C55 CDR L1: QDISNY (SEQ ID NO: 7)

[0044] C55 CDR L2: YTS (SEQ ID NO:8)

[0045] C55 CDR L3: FSELPWT (SEQ ID NO: 9)

[0046] C55 CDR H1: GFSLSTSGMG (SEQ ID NO: 10)

[0047] C55 CDR H2: IWWDDDK (SEQ ID NO: 11)

[0048] C55 CDR H3: ARSFGYGLDY (SEQ ID NO: 12)

[0049] Suitable heavy chain variable domains (VH) for use in the dual CAR BAFF-R scFv include the following heavy chain variable domains derived from monoclonal antibody clone 90 (described in more detail in PCT / US2017 / 036181), of which Hu90 HC-1, HC-2 and HC-3 are humanized:

[0050] Chi90 HC: [ka] (SEQ ID NO:13)

[0051] Hu90 HC-1: [ka] (SEQ ID NO:14)

[0052] Hu90 HC-2: [ka] (SEQ ID NO:15)

[0053] Hu90 HC-3: [ka] (SEQ ID NO:16)

[0054] Suitable light chain variable domains (VL) for use in the BAFF-R scFv of the dual CAR include the following heavy chain variable domains derived from monoclonal antibody clone 90 (described in more detail in PCT / US2017 / 036181), of which Hu90 LC-1, LC-2 and LC-3 are humanized:

[0055] Chi90 LC: [ka] (SEQ ID NO:17)

[0056] HuC90 LC-1: [ka] (SEQ ID NO:18)

[0057] Hu90 LC-2: [ka] (SEQ ID NO:19)

[0058] HuC90 LC-3: [ka] (SEQ ID NO:20)

[0059] Among the heavy chain variable domains (VH) suitable for use in the BAFF-R scFv of the dual CAR are also the following heavy chain variable domains derived from the monoclonal antibody clone 55 (described in more detail in PCT / US2017 / 036181): Of these, Hu55 HC-1, HC-2 and HC-3 are humanized.

[0060] Chi55 HC: [ka] (SEQ ID NO:21)

[0061] Hu55 HC-1: [ka] (SEQ ID NO:22)

[0062] Hu55 HC-2: [ka] (SEQ ID NO:23)

[0063] Hu55 HC-3: [ka] (SEQ ID NO:24)

[0064] Also among the light chain variable domains (VL) suitable for use in the BAFF-R scFv of the dual CAR are the following heavy chain variable domains derived from the monoclonal antibody clone 90 (described in more detail in PCT / US2017 / 036181), of which Hu55 LC-1, LC-2 and HC-3 are humanized:

[0065] Chi55 LC: [ka] (SEQ ID NO:25)

[0066] Hu55 LC-1: [ka] (SEQ ID NO:26)

[0067] Hu55 LC-2: [ka] (SEQ ID NO:27)

[0068] Hu55 LC-3: [ka] (SEQ ID NO:28)

[0069] The VH and VL domains of BAFF-R scFv can be modified. Thus, each of Hu90 LC-1, Hu90 LC-2, Hu90 LC-3, Hu90 HC-1, Hu90 HC-2 and Hu90 HC-3, Hu55 LC-1, Hu55 LC-2, Hu55 LC-3, Hu55 HC-1, Hu55 HC-2 and Hu90 HC-3 in scFv can contain 1, 2, 3, 4 or 5 single amino acid substitutions. In some cases, the substitutions are limited to the framework regions (FR) and not the CDRs. In some cases, the substitutions are conservative substitutions.

[0070] The positions of the CDRs and FRs are identified by the Kabat numbering system (Kabat et al., Nucleotide Sequences of Proteins of Immunological Interest, 5th Edition, U.S. Department of Health and Human Services, U.S. Bureau of Printing (1991)). Similarly, the positions occupied by individual residues in the light or heavy chains of an antibody may be identified by the Kabat numbering system. Thus, the positions of residues required for binding in the humanized light and heavy chains of a humanized antibody may be identified by the position of the residues according to the Kabat numbering system, as is well known in the art. As described above, a humanized antibody may be an antibody with CDRs derived from a donor antibody (e.g., mouse) and variable region frameworks (FRs) derived from a human antibody. The framework regions (FRs) are said to hold the CDRs in place in the humanized antibody. These regions are designated from the amino terminus as FR L1, FR L2, FR L3, and FR L4 for the light chain and FR H1, FR H2, FR H3, and FR H4 for the heavy chain.

[0071] CD19 scFv sequence In the BAFF-R / CD19 dual CAR, different scFvs targeting CD19 can be used.

[0072] FMC63 scFv: [ka] (SEQ ID NO:29)

[0073] FMC63VL [ka] (SEQ ID NO:30)

[0074] FMC63 VH: [ka] (SEQ ID NO:31)

[0075] Additional scFvs that bind CD19 are described in US Patent Application Publication No. 2016 / 0152723 and WO 2016 / 033570.

[0076] Spacer Region The dual and bicistronic CARs described herein can include a spacer located between the targeting domain (e.g., scFv) and the transmembrane domain. A variety of different spacers can be used. Some of them include at least a portion of a human Fc region, such as a hinge portion of a human Fc region, or a CH3 domain or a variant thereof. Table 1 below provides various spacers that can be used in the CARs described herein. Table 1: Examples of spacers [Table 1]

[0077] Some spacer regions include an immunoglobulin (e.g., IgG1, IgG2, IgG3, IgG4) hinge region, i.e., the sequence between the CH1 and CH2 domains of an immunoglobulin, e.g., all or part of an IgG4 Fc hinge or a CD8 hinge. Some spacer regions include an immunoglobulin CH3 domain or both the CH3 and CH2 domains. The immunoglobulin-derived sequence can include one or more amino acid modifications, e.g., 1, 2, 3, 4 or 5 substitutions, e.g., substitutions that reduce off-target binding.

[0078] The hinge / linker region may also comprise an IgG4 hinge region having the sequence ESKYGPPCPSCP (SEQ ID NO:34) or ESKYGPPCPPCP (SEQ ID NO:33).

[0079] The hinge / linker may also comprise the sequence ESKYGPPCPPCP (SEQ ID NO:33), followed by the linker sequence GGGSSGGGSG (SEQ ID NO:32), followed by the IgG4 CH3 sequence [ka] (SEQ ID NO: 41). Thus, the entire linker / spacer region may include the following sequence: [ka] In some cases, the spacer has 1, 2, 3, 4, or 5 single amino acid changes (e.g., conservative changes) compared to SEQ ID NO:__. In some cases, the IgG4 Fc hinge / linker region is mutated at two positions (L235E; N297Q) to reduce binding by the Fc receptor (FcR).

[0080] Transmembrane domain A variety of transmembrane domains can be used in the dual and bicistronic CARs described herein. Table 2 includes examples of suitable transmembrane domains. If a spacer region is present, the transmembrane domain is located at the carboxy terminus of the spacer region. Table 2: Examples of transmembrane domains [Table 2]

[0081] Costimulatory domain and CD3 zeta domain The costimulatory domain can be any domain suitable for use with the CD3 zeta signaling domain. In some cases, the costimulatory domain has the following sequence: [ka] (SEQ ID NO:52: LL to GG amino acid changes are double underlined). In some cases, the CD28 co-signaling domain has 1, 2, 3, 4 of 5 amino acid changes (preferably conservative and preferably not present in the underlined GG sequence) compared to SEQ ID NO:23. In some cases, the co-signaling domain has the following sequence: [ka] (SEQ ID NO:54). In some cases, the 4-1BB co-signaling domain has 1, 2, 3, 4 or 5 amino acid changes (preferably conservative) compared to SEQ ID NO:24.

[0082] The costimulatory domain is located between the transmembrane domain and the CD3ζ signaling domain. Table 3 includes examples of suitable costimulatory domains, along with the sequence of the CD3ζ signaling domain. Table 3: Examples of CD3 ζ domains and costimulatory domains [Table 3]

[0083] In various embodiments, the costimulatory domain is selected from the group consisting of a costimulatory domain shown in Table 3 or a variant thereof with 1-5 (e.g., 1 or 2) amino acid modifications, a CD28 costimulatory domain or a variant thereof with 1-5 (e.g., 1 or 2) amino acid modifications, a 4-1BB costimulatory domain or a variant thereof with 1-5 (e.g., 1 or 2) amino acid modifications, and an OX40 costimulatory domain or a variant thereof with 1-5 (e.g., 1 or 2) amino acid modifications. In certain embodiments, the 4-1BB costimulatory domain or a variant thereof has 1-5 (e.g., 1 or 2) amino acid modifications. In certain embodiments, there are two costimulatory domains, e.g., a CD28 costimulatory domain or a variant thereof with 1-5 (e.g., 1 or 2) amino acid modifications (e.g., substitutions), and a 4-1BB costimulatory domain or a variant thereof with 1-5 (e.g., 1 or 2) amino acid modifications (e.g., substitutions). In various embodiments, the 1-5 (e.g., 1 or 2) amino acid modifications are substitutions. The costimulatory domain is amino-terminal to the CD3 zeta signaling domain, and in some cases, a short linker of 2-10, e.g., 3 amino acids (e.g., GGG), is positioned between the costimulatory domain and the CD3 zeta signaling domain.

[0084] CD3ζ Signaling Domain The CD3 zeta signaling domain can be any domain suitable for use with the CD3 zeta signaling domain. In some cases, the CD3 zeta signaling domain has the following sequence: [ka] (SEQ ID NO:51). In some cases, the CD3ζ signaling has 1, 2, 3, 4 (preferably conservative) of 5 amino acid changes compared to SEQ ID NO:51.

[0085] Truncated epidermal growth factor receptor The CD3 zeta signaling domain is followed by a ribosomal skip sequence (e.g., LEGGGEGRGSLLTCGDVEENPGPR; SEQ ID NO:56) and the following sequence: [ka] This can be followed by a truncated EGFR having a sequence that is at least 90%, at least 95%, at least 98% identical (to SEQ ID NO: 57). In some cases, the truncated EGFR has 1, 2, 3, 4 (preferably conservative) of the 5 amino acid changes compared to SEQ ID NO: 57.

[0086] "Amino acid modification" refers to amino acid substitutions, insertions, and / or deletions in a protein or peptide sequence. "Amino acid substitution" or "substitution" refers to the replacement of an amino acid at a particular position in a parent peptide or protein sequence with another amino acid. The substitution can change the amino acid in the resulting protein in a non-conservative manner (i.e., by changing a codon from an amino acid belonging to a group of amino acids with a particular size or characteristics to an amino acid belonging to another group) or in a conservative manner (i.e., by changing a codon from an amino acid belonging to a group of amino acids with a particular size or characteristics to an amino acid belonging to the same group). Such conservative changes generally result in less change in the structure and function of the resulting protein. The following are examples of various groups of amino acids: 1) amino acids with non-polar R groups: alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine; 2) amino acids with uncharged polar R groups: glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine; 3) amino acids with charged polar R groups (negatively charged at pH 6.0): aspartic acid, glutamic acid; 4) basic amino acids (positively charged at pH 6.0): lysine, arginine, histidine (positively charged at pH 6.0); Another group is the amino acids with phenyl groups, phenylalanine, tryptophan, tyrosine.

[0087] The CAR can comprise a sequence that is at least 90%, at least 95%, at least 98% identical, or identical to the mature amino acid sequence shown in Figure 9 (SEQ ID NOs: 29-40), and either includes or does not include a GMCSFRa signal sequence, and either includes or does not include a T2A ribosomal skip sequence and a truncated EGFRt.

[0088] In some cases, CARs can be produced using vectors in which the CAR open reading frame is followed by a T2A ribosomal skip sequence and a truncated EGFR (EGFRt) lacking the cytoplasmic signaling tail. In this arrangement, co-expression of EGFRt provides an inert, non-immunogenic surface marker that allows accurate measurement of genetically modified cells, positive selection of genetically modified cells, and efficient cell tracking of therapeutic T cells in vivo after adoptive transfer. Efficient control of proliferation to avoid cytokine storm and off-target toxicity is a key hurdle for successful T cell immunotherapy. EGFRt incorporated into CAR lentiviral vectors can act as a suicide gene to eliminate CAR+ T cells in the event of treatment-related toxicity.

[0089] The CAR described herein is preferably produced using recombinant DNA technology, but can be produced by any means known in the art. The nucleic acid encoding several regions of the chimeric receptor can be conveniently prepared and assembled into a complete coding sequence by standard techniques of molecular cloning known in the art (such as genomic library screening, overlap PCR, primer-assisted ligation, site-directed mutagenesis, etc.). The resulting coding region is preferably inserted into an expression vector and used to transform a suitable expression host cell line, preferably a T-lymphocyte cell line, most preferably an autologous T-lymphocyte cell line.

[0090] Various T cell subsets isolated from patients can be transduced with vectors for CAR expression. Central memory T cells are one of the useful T cell subsets. Central memory T cells can be isolated from peripheral blood mononuclear cells (PBMCs) by immunomagnetically selecting cells expressing the desired receptor and selecting CD45RO+ / CD62L+ cells, for example, using a CliniMACS® device. Cells enriched for central memory T cells can be activated with anti-CD3 / CD28 and transduced with, for example, a lentiviral vector directing expression of the CAR, as well as a non-immunogenic surface marker for in vivo detection, ablation, and potential ex vivo selection. Activated / genetically modified central memory T cells can be expanded in vitro with IL-2 / IL-15 and then cryopreserved. EXAMPLES

[0091] Preparation of T cell populations for dual CAR expression The following T cell populations can be prepared for expression of the BAFF-CD19 dual CAR: CD4+ naive T cells (CD4+TN), CD8+ naive T cells (CD8+TN), CD8+ central memory T cells (CD8+TCM), CD8+ memory stem cells (CD8+MSC) and Pan T cells (Pan T). Briefly, 5 mL of blood sample is added to 5 mL of Histopaque-1077 (Sigma Aldrich). The mixture is centrifuged at 2500 RPM (room temperature, no brake) for 20 minutes. The mid-peripheral blood mononuclear cell (PBMC) layer is collected, washed with 50 mL of PBS (Corning) and centrifuged at 1500 RPM (RT) for 5 minutes. The harvested cells are mixed with 10 mL of red blood cell lysis buffer (Qiagen) and incubated for 7 minutes. The cells are then washed with PBS and centrifuged for 5 minutes (1500 RPM, RT).

[0092] Various T cell populations can be prepared using the following kits available from StemCell Technologies, Inc. using the manufacturer's instructions: EasySep™ Human Naive CD4+ T Cell Enrichment Kit (CD4+ TN), EasySep™ Human Naive CD8+ T Cell Enrichment Kit (CD8+ TN), and EasySep™ Human T Cell Enrichment Kit (Pan T). CD8+ TCM can be prepared by isolating CD8+ T cells using the EasySep™ Human CD8+ T Cell Enrichment Kit from StemCell Technologies, Inc. using the manufacturer's instructions, and then staining with CD8-PerCP-Cy5.5, CD45 RO-APC, and CD62L-PE. The stained cells are then sorted to isolate CD8+ / CD45+ / CD62L+ triple positive cells. CD8+ memory stem cells (CD8+ MSC) can be generated from CD8+ TN using the culture conditions shown in Table 4. Other T cell populations can be cultured as shown in Table 4. [Table 4] EXAMPLES

[0093] Sequencing of BAFF-R / CD19 dual CAR Various BAFF-R / CD19 dual CARs were prepared. The 1250 dual CAR (SEQ ID NO: 59) comprises, from amino to carboxy terminus: BAFF-R scFv, linker, CD19 scFv (from FMC63), IgG4 (SmP / L235E, N297Q) spacer domain, CD4 transmembrane domain, 41BB cytoplasmic domain, GG linker, and CD3 zeta signaling domain (Figure 2). The 1296 dual CAR (SEQ ID NO: 61) comprises, from amino to carboxy terminus: CD19 scFv (from FMC63), linker, BAFF-R scFv, IgG4 (SmP / L235E, N297Q) spacer domain, CD4 transmembrane domain, 41BB cytoplasmic domain, GG linker, and CD3 zeta signaling domain (Figure 3). The 1316 dual CAR (SEQ ID NO: 63) comprises, from amino to carboxy terminus: CD19 VL (from FMC63), GGGS linker, BAFF-R scFv, CD19 VH (from FMC63), IgG4 (SmP / L235E,N297Q) spacer domain, CD4 transmembrane domain, 41BB cytoplasmic domain, GG linker, and CD3 zeta signaling domain.

[0094] The bicistronic CAR expresses the BAFF-R CAR and the CD19 CAR using a lentiviral vector. The two CARs are expressed in the same T cell. The mature CD19 CAR (SEQ ID NO: 65) can include, from the amino to the carboxy terminus: CD19 scFv (from FMC63), IgG4 (SmP / L235E, N297Q) spacer domain, CD28 transmembrane domain, CD28 (GG) cytoplasmic domain, GGG linker, and CD3 signaling domain. The mature BAFF-R CAR (SEQ ID NO: 67) can include, from the amino to the carboxy terminus: BAFF-R scFv, IgG4 (SmP / L235E, N297Q) spacer domain, CD4 transmembrane domain, 4-1BB cytoplasmic domain, GGG linker, and CD3 signaling domain. Example 2 Preparation of lentiviral vector expressing BAFF-R / CD19 dual CAR

[0095] Figure 5 is a schematic diagram of the lentiviral vector for expression of the 1250 dual CAR. The 1296 dual CAR and the 1316 dual CAR were generated using similar lentiviral vectors (substitution of the svFv portion). EXAMPLES

[0096] Preparation of CAR-expressing cells Cells were activated in preparation for transduction with lentiviral vectors expressing dual CARs by mixing them with CD3 / CD28 human T cell activation beads (Thermo Fisher) at a 1:1 bead to cell ratio and incubating overnight (humidified 5% CO2, 37 °C). After incubation, cells were counted and plated at 1 × 10 in 48-well plates. 6 Cells / well were distributed. Cells were infected at MOI 1. In each case, the total culture medium was supplemented to 250 μL and centrifuged for 30 min (800 g, RT). Cells were incubated overnight (humidified 5% CO2, 37 °C) and then cultured for 10 days in the medium indicated in Table 1. Cultures of CD4+ TN, CD8+ TN, CD8+ TCM, and Pan T cells contained CD3 / CD28 beads at a cell-to-bead ratio of 1:1. Cultures of CD8+ T MSC did not contain CD3 / CD28 beads. CAR expression was assessed by the percentage of GFP-positive cells using flow cytometry. EXAMPLES

[0097] CAR expression T cells (Jurkat) were transduced with each CAR construct or an empty vector. To evaluate CAR expression, cells were stained with protein L- or EGFR-APC binding antibodies. Protein L targets the variable light chain of the scFv, and truncated EGFR is co-expressed by the CAR vector. Constructs that can properly express dual CARs were further investigated. As seen in Figure 7, dual CAR1296 and dual CAR1316 expressed the complete CAR and the EGFRt selection marker, while dual CAR1250 did not express the complete CAR. EXAMPLES

[0098] In vitro cell killing by BAFF-R-targeted CAR T cells In vitro assay using various T cell populations expressing 1296 dual CAR, 1316 dual CAR, CD19 CAR or BAFF-R CAR cells. The target cell line Nalm-6 (WT, CD19 knockout, or BAFF-R knockout mutant) was labeled with chromium-31 and incubated with effector CAR T cells. CARs included BAFF-R / CD19 dual target CAR: 1296 and 1316; single target CAR: BAFF-R CAR and CD19 CAR. Non-transduced T cells (non-CAR) were used as allogeneic controls. All T cells were derived from a single healthy donor. Chromium released from target cells due to effector T cell function was measured in a gamma counter and calculated as the maximum possible release ratio. As seen in Figure 8, 1250 dual CAR did not induce a response against BAFF-R-positive L cells suggesting that the BAFF-R-targeting scFv was not properly expressed. EXAMPLES

[0099] BAFF-R and CD19 deficient mouse model The Nalm-6 B-ALL tumor line was gene-edited with CRISPR to knock out BAFF-R or CD19. Surface protein expression was confirmed by FACS staining with commercially available BAFF-R and CD19 antibodies. Nalm-6 wild type (WT) was used as a control. FACS analysis confirms the knockout, as shown in Figure 9. EXAMPLES

[0100] CTL function of dual CAR T cells In this study, the results of which are shown in Figure 10, the target cell lines Nalm-6, WT, CD19 knockout, or BAFF-R knockout mutants were labeled with chromium-51 and incubated with effector CAR T cells. CARs included BAFF-R / CD19 dual-targeting CARs. The 1250 dual CAR CTL data suggest a possible BAFF-R targeting defect. EXAMPLES

[0101] Activity of BAFF-R / CD19 dual CAR in BAFF-R positive CD19 negative mixed B-ALL tumors Figure 11A-11B shows the 1.5 x 10 5 of RFP-negative, luciferase-expressing Nalm-6-CD19KO+2.5×10 5 The results of a study examining the effects of 1316 dual CAR and 1296NSG mice following tumor challenge IV on day 0 using a mixture of RFP-positive, luciferase-expressing Nalm-6-BAFF-RKO tumor cells. Groups of five tumor mice were then each administered 2.5 x 10 IgG as a single injection on day 10. 6 CD4 TN CAR-T + 10 6 Patients were randomized to treatment with either CD8 TN 1296 or 1316 dual CAR T cells / mouse IV. Non-transduced CD4 / CD8 T cells from the same donor were used as allogeneic controls (non-CAR). As can be seen, the survival benefit of 1316 treatment was significant compared to 1296 treatment. EXAMPLES

[0102] Degranulation of 1316 BAFF-R / CD19 dual CAR against knockout tumors CD107a degranulation was used to evaluate the efficacy of the 1316 dual CAR against knockout tumors. CD4 or CD8 BAFF-R CAR T cells were incubated with either the CD19BAFF-R+ Nalm-6 or CD19+ BAFF-RNalm-6 system. Single target CD19 or BAFF-R CAR T cells were used as controls. EXAMPLES

[0103] Activity of TN / MEM 1316 BAFF-R / CD19 dual CAR in mixed B-ALL tumors On day 0, NSG mice were administered 1 × 10 5 RFP-negative, luciferase-expressing Nalm-6-CD19KO+1×10 5 Each group of five tumor mice was then treated with a mixture of RFP-positive, luciferase-expressing Nalm-6-BAFF-RKO tumor cells at a low dose (2.8 × 10 6TN / MEM), high dose (5.6×10 6 TN / MEM) were injected once, each at 1 × 10 6 and 2 x 10 6 BAFF-R CAR T cells were generated and randomized to receive 1316 dual CAR T cells / mouse intravenously on day 9 or 5 × 10 6 Non-transduced TN / MEM cells were used as allogeneic controls (non-CAR). The survival benefit of the 1316 double CAR was significant. No significant difference in survival rate was observed between the two doses.

Claims

1. A nucleic acid molecule comprising a nucleotide sequence encoding a chimeric antigen receptor that targets both BAFF-R and CD19, the chimeric antigen receptor comprising: A targeting domain comprising, from amino terminus to carboxy terminus: a) a scFv targeting CD19 and a scFv targeting BAFF-R, or b) a VL domain of a CD19 scFv, a BAFF-R targeting scFv and a VH domain of a CD19 scFv, followed by Spacer domain, Transmembrane domain, a costimulatory domain, and a CD3ζ signaling domain; A nucleic acid molecule comprising:

2. The nucleic acid molecule of claim 1, wherein the BAFF-R scFv comprises a VH domain and a VL domain, the VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 13-16, and the VL domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 17-20.

3. The nucleic acid molecule of claim 1 or 2, wherein the BAFF-R scFv comprises a VH domain and a VL domain, the VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 21-24, and the VL domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 25-28.

4. The nucleic acid molecule of claim 1 , wherein the chimeric antigen receptor comprises an amino acid sequence selected from SEQ ID NOs: 60, 61, 62 and 63.

5. A nucleic acid molecule according to any one of claims 1 to 4, wherein there is a linker between the VL domain and the scFv and / or between the VH domain and the scFv, each of which comprises 4 to 15 amino acids, and the linker comprises only G and S.

6. The nucleic acid molecule of any one of claims 1 to 5, wherein the costimulatory domain is selected from the group consisting of a CD28 costimulatory domain or a variant thereof having one to five amino acid modifications, a 4-1BB costimulatory domain or a variant thereof having one to five amino acid modifications, and an OX40 costimulatory domain or a variant thereof having one to five amino acid modifications.

7. The nucleic acid molecule according to any one of claims 1 to 6, wherein the transmembrane domain is selected from the group consisting of a CD4 transmembrane domain or a variant thereof having one to five amino acid modifications, a CD8 transmembrane domain or a variant thereof having one to five amino acid modifications, a CD28 transmembrane domain or a variant thereof having one to five amino acid modifications, a CD3ζ transmembrane domain or a variant thereof having one to five amino acid modifications, a costimulatory domain or a variant thereof having one to five amino acid modifications, and a CD3ζ signaling domain or a variant thereof having one to five amino acid modifications.

8. The spacer domains include IgG4 hinge (S→P), IgG4 hinge, IgG4 hinge (S228P) + linker, CD28 hinge, CD8 hinge-48aa, CD8 hinge-45aa, IgG4 (HL-CH3), IgG4 (L235E, N297Q), IgG4 (S228P, L235E, N297Q), and IgG4 (CH3), as well as IgG4 hinge (S→P), IgG4 hinge The nucleic acid molecule according to any one of claims 1 to 7, wherein the nucleic acid molecule is selected from the group consisting of IgG4 hinge (S228P) + linker, CD28 hinge, CD8 hinge-48aa, CD8 hinge-45aa, IgG4 (HL-CH3), IgG4 (L235E, N297Q), IgG4 (S228P, L235E, N297Q), and each variant of IgG4 (CH3) in which 1 to 5 amino acids are modified.

9. the BAFF-R scFv comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDR L1 (SEQ ID NO:1), CDR L2 (SEQ ID NO:2) and CDR L3 (SEQ ID NO:3) and the heavy chain variable region comprising CDR H1 (SEQ ID NO:4), CDR H2 (SEQ ID NO:5) and CDR H3 (SEQ ID NO:6); or 9. The nucleic acid molecule of any one of claims 1 to 8, wherein the light chain variable region comprises CDR L1 (SEQ ID NO:7), CDR L2 (SEQ ID NO:8) and CDR L3 (SEQ ID NO:9) and the heavy chain variable region comprises CDR H1 (SEQ ID NO:10), CDR H2 (SEQ ID NO:11) and CDR H3 (SEQ ID NO:12).

10. The nucleic acid molecule according to any one of claims 1 to 9, wherein the BAFF-R scFv comprises a light chain variable domain whose amino acid sequence is selected from SEQ ID NOs: 17 to 20 and 25 to 28, and / or the BAFF-R scFv comprises a heavy chain variable domain whose amino acid sequence is selected from SEQ ID NOs: 13 to 16 and 21 to 24.

11. The CD19 scFv has a VL comprising the amino acid sequence DIQMTQTTSSLSASLGDRVTISCRASQDISKYLNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQGNTLPYTFGGGTKLEIT represented by SEQ ID NO: 31, and a VH comprising the amino acid sequence represented by the formula: EVKLQESGPGLVAPSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSALKSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQGTSVTVSS, The nucleic acid molecule of any one of claims 1 to 10, wherein the VL domain of the CD19 scFv comprises SEQ ID NO: 30 and the VH domain of the CD19 scFv comprises SEQ ID NO:

31.

12. A vector or lentiviral vector comprising a nucleic acid molecule according to any one of claims 1 to 11.

13. A population of human T cells or a population of NK cells comprising a nucleic acid molecule according to any one of claims 1 to 11 or transduced by a vector or lentiviral vector according to claim 12.

14. 14. A composition comprising the population of human T cells of claim 13 for use in a method for treating cancer in a subject by administering to the subject a therapeutically effective amount, wherein the cancer is lymphoma, leukemia, or myeloma.

15. 15. The composition of claim 14, wherein the lymphoma is mantle cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma or Burkitt's lymphoma, or the leukemia is acute lymphoblastic leukemia, chronic lymphocytic leukemia or hairy cell leukemia, or the myeloma is multiple myeloma.

16. The composition of claim 14 or 15, wherein the population of human T cells is autologous or allogeneic to the subject, or the population of human T cells comprises CD4+ cells and CD8+ cells.

Citation Information

Patent Citations

  • Chimeric antigen receptor of targeted CD19 as well as method and use for jointly expressing IL-15

    CN108728459A

  • Dual specific Anti-CD22-Anti-CD19 chimeric antigen receptors

    WO2016149578A1

  • BAFF-r targeted chimeric antigen receptor-modified t-cells and uses thereof

    WO2017214167A1

  • BAFF-r antibodies and uses thereof

    WO2017214170A2

  • Bicistronic chimeric antigen receptors and their uses

    WO2018213337A1